ATRIANCE

This brand name is authorized in Austria, Canada, Croatia, Estonia, Finland, France, Ireland, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug ATRIANCE contains one active pharmaceutical ingredient (API):

1	Nelarabine UNII 60158CV180 - NELARABINE
	Nelarabine is a pro-drug of the deoxyguanosine analogue ara-G. Accumulation of ara-GTP in leukaemic blasts allows for preferential incorporation of ara-GTP into deoxyribonucleic acid (DNA) leading to inhibition of DNA synthesis. This results in cell death. Other mechanisms may contribute to the cytotoxic effects of nelarabine. In vitro, T-cells are more sensitive than B-cells to the cytotoxic effects of nelarabine.
	Read more about Nelarabine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ATRIANCE Solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01BB07	Nelarabine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BB Purine analogues
Discover more medicines within L01BB07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02299925
EE	Ravimiamet	1306763, 1826568, 1849585, 1879702
ES	Centro de información online de medicamentos de la AEMPS	07403001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	039376, 078365
FR	Base de données publique des médicaments	66034512
GB	Medicines & Healthcare Products Regulatory Agency	122078, 391314
LT	Valstybinė vaistų kontrolės tarnyba	1027574, 1088891
NL	Z-Index G-Standaard, PRK	85030
PL	Rejestru Produktów Leczniczych	100177250
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64498001, W64498002